Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H16NO5.Na |
| Molecular Weight | 241.2168 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(C)(CO)[C@@H](O)C(=O)NCCC([O-])=O
InChI
InChIKey=GQTHJBOWLPZUOI-FJXQXJEOSA-M
InChI=1S/C9H17NO5.Na/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13;/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13);/q;+1/p-1/t7-;/m0./s1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C9H16NO5 |
| Molecular Weight | 218.227 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Pantothenic acid (known as Vitamin B5) is a water-soluble member of the B-vitamin family that is converted into 4’-phosphopantetheine, which is then converted to co-enzyme A (CoA) via adenosine triphosphate. Pantothenic acid regulates epidermal barrier function and keratinocytes differentiation via CoA metabolism. Pantothenic acid is incorporated into co-enzyme A and protects cells against peroxidative damage by increasing the level of glutathione. A recent feasibility study has also shown that daily oral supplementation of a nutritional agent containing pantothenic acid for 8 weeks was feasible and safe. It was discovered the different pharmacological implementation of pantothenic acid, such as treatment of acne, obesity. Existed some reports, mentioned efficacy using pantothenic acid in systemic lupus erythematosus. Significant reduction in morning stiffness, degree of disability, and severity of pain was reported for persons taking pantothenic acid in case of osteoarthritis and rheumatoid arthritis. Vitamin B5 may increase the effects of a group of drugs called cholinesterase inhibitors, which are used to treat Alzheimer's disease. That might lead to severe side effects.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q9BZ23|||Q8TCR5 Gene ID: 80025.0 Gene Symbol: PANK2 Target Organism: Homo sapiens (Human) |
|||
Target ID: Q8TE04 Gene ID: 53354.0 Gene Symbol: PANK1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | VITAPED Approved UseFor treatment of pernicious anemia (due to lack of or inhibition of intrinsic factor) and for prevention and treatment of vitamin B 12 deficiency. Launch Date1993 |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
672 ng/mL |
500 mg 1 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1749 ng/mL |
1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5087 ng/mL |
2000 mg 1 times / day steady-state, oral dose: 2000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3556 ng/mL |
5000 mg 1 times / day steady-state, oral dose: 5000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4464 ng/mL |
5000 mg 1 times / day steady-state, oral dose: 5000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
38820 ng × h/mL |
500 mg 1 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
24860 ng × h/mL |
1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
52460 ng × h/mL |
2000 mg 1 times / day steady-state, oral dose: 2000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
49460 ng × h/mL |
5000 mg 1 times / day steady-state, oral dose: 5000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
64180 ng × h/mL |
5000 mg 1 times / day steady-state, oral dose: 5000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
362.061 h |
500 mg 1 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
125.057 h |
1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
230.11 h |
2000 mg 1 times / day steady-state, oral dose: 2000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
240.503 h |
5000 mg 1 times / day steady-state, oral dose: 5000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
205.799 h |
5000 mg 1 times / day steady-state, oral dose: 5000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIUM PANTOTHENATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The structure of the pantothenate kinase.ADP.pantothenate ternary complex reveals the relationship between the binding sites for substrate, allosteric regulator, and antimetabolites. | 2004-08-20 |
|
| Coenzyme A biosynthesis: reconstruction of the pathway in archaea and an evolutionary scenario based on comparative genomics. | 2004-07 |
|
| Fluorimetric determination of pantothenic acid in foods by liquid chromatography with post-column derivatization. | 2004-04-30 |
|
| Determination of vitamin B5 in a range of fortified food products by reversed-phase liquid chromatography-mass spectrometry with electrospray ionisation. | 2004-04-02 |
|
| Cofactor engineering of intracellular CoA/acetyl-CoA and its effect on metabolic flux redistribution in Escherichia coli. | 2004-04 |
|
| Mitochondrial decay, a major cause of aging, can be delayed. | 2004-04 |
|
| Cell division defects of Schizosaccharomyces pombe liz1- mutants are caused by defects in pantothenate uptake. | 2004-04 |
|
| Chemo- and regioselective peptide cyclization triggered by the N-terminal fatty acid chain length: the recombinant cyclase of the calcium-dependent antibiotic from Streptomyces coelicolor. | 2004-03-16 |
|
| Are WHO/UNAIDS/UNICEF-recommended replacement milks for infants of HIV-infected mothers appropriate in the South African context? | 2004-03 |
|
| [Riboflavin-radical formation by mechanochemical solid-state reaction using stainless steel vessel]. | 2004-03 |
|
| Vanin-1(-/-) mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. | 2004-02 |
|
| Clear hydro-gel, compared to ointment, provides improved eye comfort after brief surgery. | 2004-02 |
|
| Copper-mediated synthesis of N-acyl vinylogous carbamic acids and derivatives: synthesis of the antibiotic CJ-15,801. | 2004-01-08 |
|
| One-pot chemoenzymatic preparation of coenzyme A analogues. | 2004-01-01 |
|
| Prevention of tungiasis using a biological repellent: a small case series. | 2004-01 |
|
| Organisation of the pantothenate (vitamin B5) biosynthesis pathway in higher plants. | 2004-01 |
|
| Long-term treatment of Barth syndrome with pantothenic acid: a retrospective study. | 2003-12 |
|
| Pharmacotherapy for dyslipidaemia--current therapies and future agents. | 2003-11 |
|
| Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. | 2003-10 |
|
| Substrate specificity and kinetic isotope effect analysis of the Eschericia coli ketopantoate reductase. | 2003-09-30 |
|
| Metabolic network analysis during fed-batch cultivation of Corynebacterium glutamicum for pantothenic acid production: first quantitative data and analysis of by-product formation. | 2003-09-04 |
|
| [Development of nutrient medium for the cultivation of Lactobacillus plantarum 8R-A3 ]. | 2003-08-30 |
|
| Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. | 2003-08 |
|
| Determination of water-soluble vitamins in soft drinks and vitamin supplements using capillary electrophoresis. | 2003-08 |
|
| Structure of E. coli ketopantoate hydroxymethyl transferase complexed with ketopantoate and Mg2+, solved by locating 160 selenomethionine sites. | 2003-08 |
|
| An evaluation of protein assays for quantitative determination of drugs. | 2003-07-31 |
|
| Competitive and interactions affecting a fermentative spirochete in anaerobic chemostats. | 2003-07 |
|
| Pantothenic acid quantification by a stable isotope dilution assay based on liquid chromatography-tandem mass spectrometry. | 2003-07 |
|
| The crystal structure of the first enzyme in the pantothenate biosynthetic pathway, ketopantoate hydroxymethyltransferase, from M tuberculosis. | 2003-07 |
|
| Biotin uptake by human intestinal and liver epithelial cells: role of the SMVT system. | 2003-07 |
|
| Vitamin intake in Japanese women college students. | 2003-06 |
|
| Magnetic resonance imaging and Hallervorden-Spatz syndrome. | 2003-06 |
|
| Lactation performance by dairy cows fed supplemental biotin and a B-vitamin blend. | 2003-06 |
|
| Structural insights into the evolution of the pantothenate-biosynthesis pathway. | 2003-06 |
|
| [Regulation of acetate metabolism in a strain of Acinetobacter sp., growing on ethanol]. | 2003-05-02 |
|
| Risk analysis applied to food fortification. | 2003-05 |
|
| [Advance in therapy of acute rhinitis--comparison of efficacy and safety of xylometazoline in combination xylometazoline-dexpanthenol in patients with acute rhinitis]. | 2003-04 |
|
| Use of the mannitol pathway in fructose fermentation of Oenococcus oeni due to limiting redox regeneration capacity of the ethanol pathway. | 2003-04 |
|
| [The protective effect of dexpanthenol in nasal sprays. First results of cytotoxic and ciliary-toxic studies in vitro]. | 2003-03 |
|
| Transport of biotin in human keratinocytes. | 2003-03 |
|
| Committee on food nutrition. Water-soluble vitamins. | 2003-02-28 |
|
| The optimization of HPLC-UV conditions for use with FTIR detection in the analysis of B vitamins. | 2003-02 |
|
| [Ogilvie's syndrome: a rare cause of the acute abdomen]. | 2003-02 |
|
| Specialization of function among aldehyde dehydrogenases: the ALD2 and ALD3 genes are required for beta-alanine biosynthesis in Saccharomyces cerevisiae. | 2003-01 |
|
| [Gel with provitamin B5 applied during tests with the Goldmann triple-mirror]. | 2003 |
|
| [Clinical evaluation of provitamin B5 drops and gel for postoperative treatment of corneal and conjuctival injuries]. | 2003 |
|
| Protection by pantothenic acid against apoptosis and cell damage by oxygen free radicals--the role of glutathione. | 2003 |
|
| Fermentative activity and production of volatile compounds by Saccharomyces grown in synthetic grape juice media deficient in assimilable nitrogen and/or pantothenic acid. | 2003 |
|
| Pantothenic acid: an organ-specific pro-oxidant vitamin. Brain and liver neuroprostane levels in rats fed a pantothenic acid-deficient diet. | 2002 |
|
| [Studies on calluses induced from various explants of Cistanche deserticola]. | 2001-04 |
Patents
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:34 GMT 2025
by
admin
on
Mon Mar 31 17:50:34 GMT 2025
|
| Record UNII |
OES0R93F0C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23679004
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
OES0R93F0C
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
DTXSID4047173
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
867-81-2
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
236917
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000085517
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
m8388
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | Merck Index | ||
|
OES0R93F0C
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
212-768-6
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
SUB03625MIG
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
Sodium pantothenate
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
760
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |